title: Pegfilgrastim to support CHOP-14 in elderly patients with non-Hodgkin's lymphoma.
abstract: This study investigated whether pegfilgrastim support would enable on-schedule delivery of dose-dense cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP-14) to elderly patients with non-Hodgkin's lymphoma (NHL). Thirty patients 60 years of age and older with aggressive NHL were evaluated after receiving up to six cycles of CHOP-14 supported with pegfilgrastim. The median age was 68 years (range 61 - 74). Forty-seven per cent of patients received full dose chemotherapy on schedule for all cycles (range 65 - 93). Chemotherapy was delayed in 10 patients and dose reduced in 15 patients. Hematological toxicity was the most common reason for delays and dose reduction. Six of nine patients (67%) achieved a peripheral blood CD34+ count of at least 20 cellsx106 L-1 on day 12 of cycle one. The delivery on schedule of dose-dense CHOP-14 to elderly patients with previously untreated aggressive NHL is safe and efficacious with once per cycle pegfilgrastim support.
authors.affiliation: Division of Haematology & Medical Oncology, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia. max.wolf@petermac.org
authors.forename: Max
authors.initials: M
authors.lastname: Wolf
authors.forename: Mark
authors.initials: M
authors.lastname: Bentley
authors.forename: Paula
authors.initials: P
authors.lastname: Marlton
authors.forename: Noemi
authors.initials: N
authors.lastname: Horvath
authors.forename: Ian D
authors.initials: ID
authors.lastname: Lewis
authors.forename: Andrew
authors.initials: A
authors.lastname: Spencer
authors.forename: Richard
authors.initials: R
authors.lastname: Herrmann
authors.forename: Chris
authors.initials: C
authors.lastname: Arthur
authors.forename: Simon
authors.initials: S
authors.lastname: Durrant
authors.forename: Marilyn
authors.initials: M
authors.lastname: van Kerkhoven
authors.forename: Jamie
authors.initials: J
authors.lastname: MacMillan
authors.forename: Robert
authors.initials: R
authors.lastname: Mrongovius
mesh_terms: D000368:Aged; D018952:Antigens, CD34 / Q000378:metabolism; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D007958:Leukocyte Count; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009504:Neutrophils / Q000166:cytology / Q000187:drug effects; D011092:Polyethylene Glycols; D011241:Prednisone / Q000627:therapeutic use; D011994:Recombinant Proteins; D016896:Treatment Outcome; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D018952:Antigens, CD34; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; C455861:pegfilgrastim; D011092:Polyethylene Glycols; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D000069585:Filgrastim; D011241:Prednisone